Registrational Trial

A registrational trial — also called a pivotal trial — is a clinical study designed and conducted specifically to generate the primary efficacy and safety evidence submitted in a marketing application, most commonly a New Drug Application (NDA) or Biologics License Application (BLA) to FDA, or the equivalent dossier to another regulator. The defining feature is regulatory purpose and design intent, not phase number: a registrational trial is prospectively built as an adequate and well-controlled investigation under 21 CFR 314.126, with a single prespecified primary endpoint, a locked statistical analysis plan, and a sample size set by an a priori power calculation — typically agreed with the regulator in advance through a Special Protocol Assessment.

Why the distinction matters

Section 505(d) of the Federal Food, Drug, and Cosmetic Act requires ‘substantial evidence’ of effectiveness before FDA can approve a new drug, and FDA has long interpreted that historically to mean results from more than one adequate and well-controlled trial. FDA’s guidance Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products describes both the conventional two-trials expectation and the narrower circumstances — an unusually persuasive single-trial result plus strong corroborating evidence — under which one pivotal trial can be sufficient. Calling a trial ‘registrational’ signals to everyone involved (sponsors, CROs, biostatisticians, regulatory affairs staff, and research administrators managing the underlying grants or budgets) that its design cannot be altered opportunistically after the fact: the primary endpoint, population, and analysis are fixed before unblinding precisely because this is the evidence a marketing approval decision will rest on.

How it differs from exploratory and early-phase trials

Phase 1 studies (tolerability, pharmacokinetics) and most Phase 2 studies (dose-finding, early efficacy signal, hypothesis generation) are exploratory: they are not powered on a confirmatory clinical endpoint and are not designed, on their own, to satisfy the substantial-evidence standard. Their data can and does appear in a marketing application as supportive context, but they are not the trial the application’s efficacy claim is built on. See CASRAI’s clinical trial phases guide for the full Phase 1–4 sequence. A registrational trial is usually, but not always, a Phase 3 study — accelerated-approval and some rare-disease programs instead rely on a well-controlled Phase 2 trial measuring a surrogate or intermediate endpoint, with a confirmatory Phase 3 or Phase 4 trial required afterward to verify the predicted clinical benefit.

How it relates to late-phase studies

CASRAI’s dictionary separately covers the Late-Phase Clinical Study — the industry convention for Phase IIIb and Phase IV studies conducted at or after NDA/BLA submission. The two concepts are easy to conflate but describe different things: ‘registrational’ is about a trial’s evidentiary role in an approval decision, while ‘late-phase’ is about timing relative to submission. A Phase IIIb trial run in parallel with the initial pivotal submission is not itself registrational for that first approval, but a similarly timed trial can become registrational later if it is the pivotal evidence for a subsequent supplemental application or label expansion.

Operational implications for research administration

Because a registrational trial’s protocol, endpoints, and statistical plan are effectively frozen once agreed with the regulator, budget and timeline changes downstream of that agreement carry outsized risk — a protocol amendment that alters the primary endpoint after alignment with FDA can require renegotiating the regulatory pathway itself, not just an IRB or contract amendment. Research administrators supporting registrational-stage work typically see heavier data-management, monitoring, and quality-assurance requirements (including readiness for an FDA BIMO inspection) than at earlier phases, reflecting the trial’s direct evidentiary weight in an approval decision.

Frequently Asked Questions

Is a registrational trial the same as a pivotal trial?

Yes — the terms are used interchangeably. Both describe a clinical study designed and conducted specifically to generate the primary efficacy and safety evidence submitted in a marketing application, such as an NDA or BLA to FDA or an equivalent dossier to another regulator.

Is a registrational trial always a Phase 3 study?

Usually, but not always. What makes a trial registrational is its regulatory purpose and design — a single prespecified primary endpoint, a locked statistical analysis plan, and a sample size set by an a priori power calculation — not its phase number. In accelerated-approval and some rare-disease programs, a well-controlled Phase 2 trial measuring a surrogate or intermediate endpoint can serve as the registrational trial, with a confirmatory Phase 3 or Phase 4 trial required afterward.

Can a single trial support FDA approval, or are two trials always required?

FDA has historically interpreted the Federal Food, Drug, and Cosmetic Act’s ‘substantial evidence’ standard to mean results from more than one adequate and well-controlled trial. FDA guidance also describes narrower circumstances — an unusually persuasive single-trial result plus strong corroborating evidence — under which one pivotal trial can be sufficient.

Is a registrational trial the same as a registry study?

No. A registry study is typically an observational effort that tracks patients or outcomes over time, without the prespecified primary endpoint, locked analysis plan, and controlled design that a regulator requires of the ‘adequate and well-controlled investigation’ behind a marketing application. A registrational trial refers specifically to that controlled, confirmatory study submitted to support approval.

How is a registrational trial different from a late-phase clinical study?

The two describe different things. ‘Registrational’ is about a trial’s evidentiary role in an approval decision, while ‘late-phase’ is about timing relative to submission — Phase IIIb and Phase IV studies conducted at or after NDA/BLA submission. A late-phase trial run alongside an initial pivotal submission isn’t itself registrational for that approval, but it can become registrational later if it becomes the pivotal evidence for a subsequent supplemental application. See CASRAI’s Late-Phase Clinical Study entry for more.